You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧泰(688177.SH)2020年營收達1.85億元 投入研發費用5.63億元
格隆匯 03-05 13:02

格隆匯3月5日丨百奧泰(688177.SH)披露2020年年度報吿,報吿期內,公司實現營業收入1.85億元,同比增長263.27倍;歸屬於上市公司股東的淨虧損5.13億元,同比減虧49.81%;歸屬於上市公司股東的扣除非經常性損益的淨虧損5.62億元,同比減虧17.98%;基本每股虧損1.27元。2020年度公司研發費用為5.63億元。

公司自主研發的阿達木單抗生物類似藥BAT1406的上市申請於2018年8月17日正式獲得CDE受理,並於2019年11月獲得國家藥監局的上市批准,商品名為“格樂立”,是國內首個獲得上市批准的阿達木單抗生物類似藥。2020年1月,格樂立正式上市銷售。截至2020年12月31日,格樂立獲批適應症為強直性脊柱炎、類風濕關節炎、銀屑病、克羅恩病和葡萄膜炎。

截至目前,公司有1個產品獲得上市批准,有20個在研產品,其中2個產品已經提交上市申請,3個產品處於III期臨牀研究階段,2個產品處II期臨牀研究階段,3個產品處於I期臨牀研究階段,公司另有多個創新抗體在研藥物處於臨牀前研究階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account